Yvonne Freund-Levi
0000-0001-6863-6679
Karolinska Institute
62 papers found
Refreshing results…
Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study
Galantamine versus Risperidone for Agitation in People with Dementia: A Randomized, Twelve-Week, Single-Center Study
Galantamine Versus Risperidone Treatment of Neuropsychiatric Symptoms in Patients with Probable Dementia: An Open Randomized Trial
Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-β42 by Human Microglia and Decrease Inflammatory Markers
Effects on Transthyretin in Plasma and Cerebrospinal Fluid by DHA-Rich n-3 Fatty Acid Supplementation in Patients with Alzheimer's Disease: The OmegAD Study
Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer’s disease patients
Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood Mononuclear Leukocytes: The OmegAD Study
Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid
Agitation - relation to clinical and dementia biomarkers in cerebrospinal fluid
Reduced prostaglandin F-2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study
Omega Fatty Acid Supplementation Effects on Weight and Appetite in Patients with Alzheimer's Disease: The Omega-3 Alzheimer's Disease Study (vol 57, pg 11, 2009)
Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer’s Disease: The OmegAD Study
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Detection of amyloid in Alzheimer's disease with positron emission tomography using [C-11]AZD2184
Omega-3 Fatty Acid Supplementation Effects on Weight and Appetite in Patients with Alzheimer's Disease: The Omega-3 Alzheimer's Disease Study
Effects of docosahexaenoic acid–rich n−3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
[Omega-3-fatty acids protect against dementia. Also early symptoms of mild Alzheimer disease seem to be inhibited]
omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study - A randomized double-blind trial
[Administration of symptom-relieving drugs in Alzheimer disease is beneficial]
Missing publications? Search for publications with a matching author name.